Trials / Completed
CompletedNCT05304910
A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Single-dose Study Investigating the Safety, Tolerability and Pharmacokinetic Properties of Lu AG09222 in Healthy Caucasian, Chinese and Japanese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main goal of the study is to learn more about how the body absorbs and eliminates Lu AG09222 after a single dose is injected under the skin. Researchers will also investigate safety and tolerability effects of Lu AG09222 after administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lu AG09222 | Lu AG09222 will be administered per schedule specified in the arm description. |
| DRUG | Placebo | Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description. |
Timeline
- Start date
- 2022-03-18
- Primary completion
- 2022-10-30
- Completion
- 2022-10-30
- First posted
- 2022-03-31
- Last updated
- 2022-11-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05304910. Inclusion in this directory is not an endorsement.